Pegvisomant; Pegylated human growth hormone

Specification

• Cat#: THP-0033
• Product Name: Pegvisomant; Pegylated human growth hormone
• Cas No: 218620-50-9
• Description: The product is a highly selective growth hormone (GH) receptor antagonist. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), it actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
• Sequences: FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF
• Species: Human
• Molecular Weight: 22129.0 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C990H1532N262O300S7
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Application: The product is a growth hormone receptor antagonist used for the treatment of acromegaly.
• Concentration: 10 mg/ml

Pharmaceutical Information

• Pharmaceutical Application: Pegvisomant
• Targets: Target 1. Growth hormone receptor; Enzyme 1. Sterol 26-hydroxylase, mitochondrial; Enzyme 2. Glutamine synthetase; Enzyme 3. Cytochrome P450 2C18; Enzyme 4. Cytochrome P450 3A4; Enzyme 5. Cholinesterase; Enzyme 6. Cytochrome P450 2C19; Enzyme 7. Cytochrome P450 4A11